image credit: Adobe Stock

iTolerance and Northway Biotech Form Manufacturing Pact for Fusion Protein

August 4, 2023

On Aug. 1, 2023, US-based iTolerance, an early-stage regenerative medicine company, and Lithuania-based Northway Biotech, a contract development and manufacturing organization, announced that they have entered into an agreement for the manufacturing of Streptavidin-FasL (SA-FasL) fusion protein, an important component of iTolerance’s proprietary iTOL-100 platform technology.

According to a company press release, the SA-FasL fusion protein has demonstrated promising potential in pre-clinical studies; it was shown to establish durable, localized immune tolerance, which would thus enable implanted tissue or organoid, or a cell therapy, to function as a viable replacement for damaged native cells.

Read More on Biopharm International